Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.

Revital Nimri¹, Benyamin Grosman², Anirban Roy², Judith Nir¹, Naama Fisch Shvalb¹, Natali Kurtz², Neta Loewenthal^3,4, Michal Gillon-Keren¹, Ido Muller⁵, Eran Atlas⁵, Moshe Phillip^1,6

¹The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

²Medtronic Diabetes, Northridge, California, USA.

³Pediatric Endocrinology Unit, Soroka University Medical Center, Beer Sheva, Israel.

⁴Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

⁵DreaMed Diabetes Ltd., Petah Tikvah, Israel.

⁶Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PubMed DOI

Abstract

Background: The Medtronic MiniMed™ 670G system adjusts basal insulin delivery in response to continuous glucose monitoring levels and is already in use in clinical practice. We tested the home-based feasibility of the new MiniMed advanced hybrid closed-loop (AHCL) system, which includes several algorithm enhancements and an optional autocorrection bolus mode. Methods: Twelve adolescents and young…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.